With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive ...

CDASI-A score at 12 weeks was significantly lower in dazukibart 600 mg versus placebo, suggesting reduced morbidity. 2.

Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...

Achievement of cancer remission was associated with dermatomyositis complete clinical response among patients with cancer-associated DM.

A "groundbreaking" £1.65 million treatment has been approved for use on the NHS, offering patients with severe sickle cell disease some hope of a cure. It is believed around 1,700 people could be ...

The recovery can extend from anywhere between six to 12 months and occasionally up to three years. Currently, there is no certain cure for Guillain-Barré Syndrome. The paralysis not only affects the ...

Dermatomyositis and lupus may share symptoms in some cases. Here's what you need to know about these autoimmune conditions.

“[By] using these techniques, I now offer a holistic and comprehensive treatment that promises not just relaxation, but transformative rejuvenation” — which is, exactly where the cultural ...

The study included patients with cutaneous dermatomyositis and those with muscle involvement. Treatment-emergent adverse events occurred in 80% and 81% of dazukibart 150 mg and 160 mg groups.

Received FDA orphan drug designation for the treatment of dermatomyositis in April 2017. Received FDA approval for the treatment of dermatomyositis in adults in July 2021. The mechanism of action ...

and Rare Pediatric Disease Designation for the treatment of juvenile dermatomyositis. Any statements in this press release about the future expectations, plans and prospects of the Company, including ...